首页> 外文期刊>Current problems in pediatric and adolescent health care >Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management
【24h】

Antidepressant-Induced Activation in Children and Adolescents: Risk, Recognition and Management

机译:儿童和青少年的抗抑郁诱导的活化:风险,认可和管理

获取原文
获取原文并翻译 | 示例
       

摘要

The tolerability of antidepressants is poorly characterized in children and adolescents with depressive and anxiety disorders. Among adverse events that affect the tolerability of antidepressants in youth is activation, a cluster of symptoms that represent a hyperarousal event characterized by impulsivity, restlessness, and/or insomnia. This cluster of symptoms was first identified as a side effect of selective serotonin and selective serotonin norepinephrine inhibitors (SSRIs and SSNRIs) in the early 1990s; however, activation remains poorly characterized in terms of prevalence, risk factors, and pathophysiology. This article describes the pathophysiology of antidepressant-related activation, predictors of activation and its clinical management in youth with depressive and anxiety disorders who are treated with antidepressant medications.
机译:抗抑郁药的可耐受性在患有抑郁和焦虑症的儿童和青少年中表现不佳。 在影响青少年抗抑郁药的耐受性的不良事件中,一种症状,代表一种以冲动,躁动和/或失眠为特征的静脉曲张的症状。 该症状首先被鉴定为20世纪90年代初期选择性血清素和选择性血清素Norepinephrine抑制剂(SSRIS和SSNRIS)的副作用; 然而,在患病率,危险因素和病理生理学方面,激活仍然差。 本文介绍了与抗抑郁药物治疗的抑郁和焦虑症的青春期抗抑郁相关激活,激活预测因子及其临床管理的病理生理学。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号